Ali Nokhodchi, Davoud Hassan-Zadeh, Farnaz Monajjem-Zadeh and Nita Taghi-Zadeh
Effect of various surfactants and their concentration on controlled release of captopril from polymeric matrices
Various methods are available to formulate water soluble drugs into sustained release dosage forms by retarding the dissolution rate. One of the methods used to control drug release and thereby prolong therapeutic activity is to use hydrophilic and lipophilic polymers. In this study, the effects of various polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose (EC) and sodium carboxymethylcellulose (CMC) and surfactants (sodium lauryl sulphate, cetyltrimethylammonium bromide and Arlacel 60) on the release rate of captopril were investigated. The results showed that an increase in the amount of HPMC K15M resulted in reduction of the release rate of captopril from these matrices. When HPMC was partly replaced by NaCMC (the ratio of HPMC/NaCMC was 5:1), the release rate of the drug significantly decreased. However, there was no significant difference in release rate of captopril from matrices produced with ratios of 5:1 and 2:1 of HPMC/NaCMC. The presence of lactose in matrices containing HPMC and NaCMC increased the release rate of captopril. It was interesting to note that although partial replacement of HPMC by EC reduced the release rate of the drug (ratio of HPMC/EC 2:1), the release rate was increased when the ratio of HPMC/EC was reduced to 1:1. The effects of various surfactants on the release rate of captopril from HPMC/EC (1:1) matrices were also investigated. The results showed that the surfactants did not significantly change the release rate of the drug. Release data were examined kinetically and the ideal kinetic models were estimated for the drug release. The kinetic analysis of drug release data from various formulations showed that incorporation of surfactants in HPMC/EC matrices did not produce a zero-order release pattern.
Affidah Sabran, Endang Kumolosasi and Ibrahim Jantan
induction of annexin 1 in human peripheral blood mononuclear cells and their inhibitory effect on secretory phospholipase A 2 , Trop. J. Pharm. Res. 13 (2014) 171–177; https://doi.org/10.4314/tjpr.v13i2.1
12. L. Parente and E. Solito, Annexin 1: More than an anti-phospholipase protein, Inflamm . Res . 53 (2004) 125–132; https://doi.org/10.1007/s00011-003-1235-z
13. L. H. K. Lim and S. Pervaiz, Annexin 1 : the new face of an old molecule, FASEB J. 24 (2007) 968–975; https://doi.org/10.1096/fj.06-7464rev
14. C. Guo, S. Liu and M-Z. Sun